RSI Oversold Stocks
PSTV is flagged as RSI oversold, meaning recent selling pressure has pushed momentum to extreme levels that may lead to a short-term rebound.
PLUS THERAPEUTICS INC (PSTV) Stock Price & Overview
NASDAQ:PSTV • US72941H5090
Current stock price
2.92 USD
-0.41 (-12.31%)
At close:
2.86 USD
-0.06 (-2.05%)
After Hours:
The current stock price of PSTV is 2.92 USD. Today PSTV is down by -12.31%. In the past month the price decreased by -60.43%. In the past year, price decreased by -84.43%.
PSTV Key Statistics
52-Week Range2.9 - 30.5
Current PSTV stock price positioned within its 52-week range.
1-Month Range2.9 - 8.2
Current PSTV stock price positioned within its 1-month range.
- Market Cap
- 500.926M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.21
- Dividend Yield
- N/A
PSTV Stock Performance
Today
-12.31%
1 Week
-45.57%
1 Month
-60.43%
3 Months
-78.96%
Longer-term
6 Months -83.25%
1 Year -84.43%
2 Years -93.29%
3 Years -97.00%
5 Years -99.66%
10 Years N/A
PSTV Stock Chart
PSTV Stock Screens
PSTV currently appears in the following ChartMill screener lists.
PSTV Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to PSTV. When comparing the yearly performance of all stocks, PSTV is a bad performer in the overall market: 99.03% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
PSTV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PSTV. PSTV may be in some trouble as it scores bad on both profitability and health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
PSTV Earnings
On March 12, 2026 PSTV reported an EPS of -1.04 and a revenue of 1.37M. The company missed EPS expectations (-25.16% surprise) and beat revenue expectations (4.27% surprise).
Next Earnings DateMay 28, 2026
Last Earnings DateMar 12, 2026
PeriodQ4 / 2025
EPS Reported-$1.04
Revenue Reported1.367M
EPS Surprise -25.16%
Revenue Surprise 4.27%
PSTV Forecast & Estimates
For the next year, analysts expect an EPS growth of 94.67% and a revenue growth 17.05% for PSTV
Analysts
Analysts80
Price TargetN/A
EPS Next Y94.67%
Revenue Next Year17.05%
PSTV Groups
Sector & Classification
PSTV Financial Highlights
Over the last trailing twelve months PSTV reported a non-GAAP Earnings per Share(EPS) of -3.21. The EPS decreased by -47.8% compared to the year before.
Income Statements
Revenue(TTM)5.21M
Net Income(TTM)-22.39M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -137.13% | ||
| ROE | -560.21% | ||
| Debt/Equity | 0.19 |
Chartmill High Growth Momentum
EPS Q2Q%-111.68%
Sales Q2Q%-3.19%
EPS 1Y (TTM)-47.8%
Revenue 1Y (TTM)-10.49%
PSTV Ownership
Ownership
Inst Owners12.99%
Shares171.55M
Float169.42M
Ins Owners0.34%
Short Float %11.87%
Short Ratio2.42
PSTV Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.91 | 365.463B | ||
| AMGN | AMGEN INC | 14.9 | 184.669B | ||
| GILD | GILEAD SCIENCES INC | 15.7 | 173.96B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.28 | 110.325B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.26 | 80.669B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.82 | 43.81B | ||
| INSM | INSMED INC | N/A | 35.309B | ||
| NTRA | NATERA INC | N/A | 29.036B | ||
| BIIB | BIOGEN INC | 10.92 | 25.293B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.94 | 24.53B | ||
| MRNA | MODERNA INC | N/A | 19.261B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.898B | ||
| INCY | INCYTE CORP | 12.23 | 18.878B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PSTV
Company Profile
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The company is headquartered in Austin, Texas. The company went IPO on 2000-08-09. The firm is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
Company Info
IPO: 2000-08-09
PLUS THERAPEUTICS INC
4200 Marathon Blvd., Suite 200
Austin TEXAS 78756 US
CEO: Marc. H. Hedrick
Employees: 21
Phone: 17372557194
PLUS THERAPEUTICS INC / PSTV FAQ
What does PSTV do?
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The company is headquartered in Austin, Texas. The company went IPO on 2000-08-09. The firm is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
What is the stock price of PLUS THERAPEUTICS INC today?
The current stock price of PSTV is 2.92 USD. The price decreased by -12.31% in the last trading session.
What is the dividend status of PLUS THERAPEUTICS INC?
PSTV does not pay a dividend.
How is the ChartMill rating for PLUS THERAPEUTICS INC?
PSTV has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does PLUS THERAPEUTICS INC belong to?
PLUS THERAPEUTICS INC (PSTV) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for PLUS THERAPEUTICS INC?
PLUS THERAPEUTICS INC (PSTV) has a market capitalization of 500.93M USD. This makes PSTV a Small Cap stock.